Oxford BioDynamics extends payment deadline for investor

Oxford BioDynamics Plc has granted an extension to the payment deadline for £250,000 owed to investor Vulpes Investment Management, according to a press release. The company raised £9.15 million through a recent share placement, which took place on August 10, 2026. The shares were admitted to trading on the Alternative Investment Market (AIM) on August 27, 2026.

Vulpes Investment Management, through its managed funds, agreed to subscribe for 500 million of the placing shares for £500,000. To date, the company has received £250,000 of the outstanding amount, with the remaining £250,000 to be paid by October 30, 2026. The extension was requested by Vulpes and agreed upon by Oxford BioDynamics, Singer Capital Markets, and Merlin Partners LLP.

The transaction is considered a related party under AIM Rule 13 due to Martin Diggle's dual role as a non-executive director of Oxford BioDynamics and co-founder of Vulpes. Excluding the unpaid shares, Vulpes holds 868.5 million ordinary shares, representing 6.46% of the company's issued share capital. Independent directors Dr. David Holbrook and Peter Presland reviewed the amendment to the placing agreement terms and deemed it fair and reasonable for shareholders.